215 related articles for article (PubMed ID: 31877173)
1. The use of back propagation neural networks and 18F-Florbetapir PET for early detection of Alzheimer's disease using Alzheimer's Disease Neuroimaging Initiative database.
Ozsahin I; Sekeroglu B; Mok GSP
PLoS One; 2019; 14(12):e0226577. PubMed ID: 31877173
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
[TBL] [Abstract][Full Text] [Related]
4. Relationship of Hippocampal Volume to Amyloid Burden across Diagnostic Stages of Alzheimer's Disease.
Trzepacz PT; Hochstetler H; Yu P; Castelluccio P; Witte MM; Dell'Agnello G; Degenhardt EK;
Dement Geriatr Cogn Disord; 2016; 41(1-2):68-79. PubMed ID: 26625159
[TBL] [Abstract][Full Text] [Related]
5. Amyloid deposition, hypometabolism, and longitudinal cognitive decline.
Landau SM; Mintun MA; Joshi AD; Koeppe RA; Petersen RC; Aisen PS; Weiner MW; Jagust WJ;
Ann Neurol; 2012 Oct; 72(4):578-86. PubMed ID: 23109153
[TBL] [Abstract][Full Text] [Related]
6. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
[TBL] [Abstract][Full Text] [Related]
7. Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume.
Caldwell JZK; Berg JL; Cummings JL; Banks SJ;
Alzheimers Res Ther; 2017 Sep; 9(1):72. PubMed ID: 28899422
[TBL] [Abstract][Full Text] [Related]
8. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
9. Multi-Modality Cascaded Convolutional Neural Networks for Alzheimer's Disease Diagnosis.
Liu M; Cheng D; Wang K; Wang Y;
Neuroinformatics; 2018 Oct; 16(3-4):295-308. PubMed ID: 29572601
[TBL] [Abstract][Full Text] [Related]
10. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
11. Multimodal Classification of Mild Cognitive Impairment Based on Partial Least Squares.
Wang P; Chen K; Yao L; Hu B; Wu X; Zhang J; Ye Q; Guo X;
J Alzheimers Dis; 2016 Aug; 54(1):359-71. PubMed ID: 27567818
[TBL] [Abstract][Full Text] [Related]
12. Predicting cognitive decline with deep learning of brain metabolism and amyloid imaging.
Choi H; Jin KH;
Behav Brain Res; 2018 May; 344():103-109. PubMed ID: 29454006
[TBL] [Abstract][Full Text] [Related]
13. Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
Namiki C; Takita Y; Iwata A; Momose T; Senda M; Okubo Y; Joshi AD; Lu M; Agbulos A; Breault C; Pontecorvo MJ
Ann Nucl Med; 2015 Aug; 29(7):570-81. PubMed ID: 25943346
[TBL] [Abstract][Full Text] [Related]
14. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic value of amyloid PET textural and shape features: comparison with classical semi-quantitative rating in 760 patients from the ADNI-2 database.
Ben Bouallègue F; Vauchot F; Mariano-Goulart D; Payoux P
Brain Imaging Behav; 2019 Feb; 13(1):111-125. PubMed ID: 29427064
[TBL] [Abstract][Full Text] [Related]
16. A Deep Learning Approach for Automated Diagnosis and Multi-Class Classification of Alzheimer's Disease Stages Using Resting-State fMRI and Residual Neural Networks.
Ramzan F; Khan MUG; Rehmat A; Iqbal S; Saba T; Rehman A; Mehmood Z
J Med Syst; 2019 Dec; 44(2):37. PubMed ID: 31853655
[TBL] [Abstract][Full Text] [Related]
17. Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth.
Murphy KR; Landau SM; Choudhury KR; Hostage CA; Shpanskaya KS; Sair HI; Petrella JR; Wong TZ; Doraiswamy PM;
Neuroimage; 2013 Sep; 78():474-80. PubMed ID: 23624169
[TBL] [Abstract][Full Text] [Related]
18. A Classification Algorithm by Combination of Feature Decomposition and Kernel Discriminant Analysis (KDA) for Automatic MR Brain Image Classification and AD Diagnosis.
Elahifasaee F; Li F; Yang M
Comput Math Methods Med; 2019; 2019():1437123. PubMed ID: 32082407
[TBL] [Abstract][Full Text] [Related]
19. Cortical graph neural network for AD and MCI diagnosis and transfer learning across populations.
Wee CY; Liu C; Lee A; Poh JS; Ji H; Qiu A;
Neuroimage Clin; 2019; 23():101929. PubMed ID: 31491832
[TBL] [Abstract][Full Text] [Related]
20. Multivariate analysis of structural MRI and PET (FDG and 18F-AV-45) for Alzheimer's disease and its prodromal stages.
Zhou Q; Goryawala M; Cabrerizo M; Barker W; Loewenstein D; Duara R; Adjouadi M
Annu Int Conf IEEE Eng Med Biol Soc; 2014; 2014():1051-4. PubMed ID: 25570142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
